Single nucleotide polymorphisms of one-carbon metabolism and cancers of the esophagus, stomach, and liver in a Chinese population. by Chang, Shen-Chih et al.
UCLA
UCLA Previously Published Works
Title
Single nucleotide polymorphisms of one-carbon metabolism and cancers of the esophagus, 
stomach, and liver in a Chinese population.
Permalink
https://escholarship.org/uc/item/0s88m9mc
Journal
PloS one, 9(10)
ISSN
1932-6203
Authors
Chang, Shen-Chih
Chang, Po-Yin
Butler, Brendan
et al.
Publication Date
2014
DOI
10.1371/journal.pone.0109235
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Single Nucleotide Polymorphisms of One-Carbon
Metabolism and Cancers of the Esophagus, Stomach, and
Liver in a Chinese Population
Shen-Chih Chang1, Po-Yin Chang1, Brendan Butler1, Binh Y. Goldstein1, Lina Mu2, Lin Cai3,
Nai-Chieh Y. You1, Aileen Baecker1, Shun-Zhang Yu4, David Heber5, Qing-Yi Lu5, Liming Li6,
Sander Greenland1,7, Zuo-Feng Zhang1*
1Department of Epidemiology, University of California Los Angeles Fielding School of Public Health, Los Angeles, CA, United States of America, 2Department of Social
and Preventive Medicine, State University of New York at Buffalo, Buffalo, NY, United States of America, 3Department of Epidemiology, Fujian Medical University, Fuzhou,
Fujian, China, 4Department of Epidemiology, Fudan University School of Public Health, Shanghai, China, 5Center for Human Nutrition, University of California Los
Angeles David Geffen School of Medicine, Los Angeles, CA, United States of America, 6Department of Epidemiology, Peking University School of Public Health, Beijing,
China, 7Department of Statistics, University of California Los Angeles College of Letters and Science, Los Angeles, CA, United States of America
Abstract
One-carbon metabolism (folate metabolism) is considered important in carcinogenesis because of its involvement in DNA
synthesis and biological methylation reactions. We investigated the associations of single nucleotide polymorphisms (SNPs)
in folate metabolic pathway and the risk of three GI cancers in a population-based case-control study in Taixing City, China,
with 218 esophageal cancer cases, 206 stomach cancer cases, 204 liver cancer cases, and 415 healthy population controls.
Study participants were interviewed with a standardized questionnaire, and blood samples were collected after the
interviews. We genotyped SNPs of the MTHFR, MTR, MTRR, DNMT1, and ALDH2 genes, using PCR-RFLP, SNPlex, or TaqMan
assays. To account for multiple comparisons and reduce the chances of false reports, we employed semi-Bayes (SB)
shrinkage analysis. After shrinkage and adjusting for potential confounding factors, we found positive associations between
MTHFR rs1801133 and stomach cancer (any T versus C/C, SB odds-ratio [SBOR]: 1.79, 95% posterior limits: 1.18, 2.71) and
liver cancer (SBOR: 1.51, 95% posterior limits: 0.98, 2.32). There was an inverse association between DNMT1 rs2228612 and
esophageal cancer (any G versus A/A, SBOR: 0.60, 95% posterior limits: 0.39, 0.94). In addition, we detected potential
heterogeneity across alcohol drinking status for ORs relating MTRR rs1801394 to esophageal (posterior homogeneity
P= 0.005) and stomach cancer (posterior homogeneity P= 0.004), and ORs relating MTR rs1805087 to liver cancer (posterior
homogeneity P= 0.021). Among non-alcohol drinkers, the variant allele (allele G) of these two SNPs was inversely associated
with the risk of these cancers; while a positive association was observed among ever-alcohol drinkers. Our results suggest
that genetic polymorphisms related to one-carbon metabolism may be associated with cancers of the esophagus, stomach,
and liver. Heterogeneity across alcohol consumption status of the associations between MTR/MTRR polymorphisms and
these cancers indicates potential interactions between alcohol drinking and one-carbon metabolic pathway.
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Introduction
Upper gastrointestinal (GI) cancers are major causes of
morbidity and mortality throughout the world. Based on
GLOBOCAN 2012 estimates, stomach, liver, and esophageal
cancers are the fifth, sixth, and eighth most common cancers,
respectively, with a global incidence of approximately 2,189,829
new cancer cases (15.5% of the total), and 1,868,700 deaths
(22.8% of the total) [1]. The majority of these cancer cases
(1,694,874 cases, 77.4%) occur in less developed countries. China
alone accounts for almost half of all incident GI cancers (1,023,072
cases, 46.7%) [1].
Continued research regarding the involvement of single
nucleotide polymorphisms (SNPs) in the etiology of these three
upper GI cancers has been fruitful. Of particular interest are the
SNPs located within genes involved in folate metabolism [2–4].
Folate maintains DNA stability by regulating DNA biosynthesis,
DNA repair and DNA methylation [5]. Neoplasms may develop
when this pathway is disregulated by the depletion of micronu-
trients or through the incorporation of polymorphisms [5]. Several
enzymes are involved in one-carbon metabolism, including the
methylenetetrahydrofolate reductase (MTHFR), methionine syn-
thase (MTR), methionine synthase reductase (MTRR), DNA
methyltransferases (DNMTs), and mitochondrial aldehyde dehy-
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drogenase 2 (ALDH2). MTHFR, MTR, and MTRR are involved
in DNA synthesis, and the generation of S-adenosylmethionine
(SAM)—a universal methyl-donor for methylation reactions.
DNMTs catalyze DNA methylation and replicate methylation
patterns. ALDH2 is responsible for metabolizing acetaldehyde
generated during alcohol metabolism. Alcohol and acetaldehyde
can inhibit folate absorption and impair DNA methylation [6].
The role of folate and one-carbon metabolism in upper GI
cancers is not fully understood. Animal studies provided some
evidence for an effect of low folate levels in oxidative stress, DNA
methylation, and hepatocarcinogenesis [7,8]; while high folate
intake can increase global DNA methylation and reduce gastric
cancer risk [9,10]. Epidemiologic studies have suggested that
genetic polymorphisms of genes in one-carbon metabolic pathway
might modulate the risk of esophageal and gastric cancer [4].
However, published results are inconclusive and limited in terms
of the number of genes/polymorphisms being investigated.
Possible modification by related micronutrients and known risk
factors has seldom been explored. Therefore, considering the
importance of one-carbon metabolism in upper GI cancer
development, we examined the associations between eight SNPs
in genes in one-carbon metabolic pathway and cancers of the
esophagus, stomach, and liver in a Chinese population. We also
evaluated heterogeneity of the associations across different strata of
plasma micronutrients (including folate, vitamin B12, and total
homocysteine) and known risk factors for these cancers.
Materials and Methods
Ethics statement
This study was exempted by the institutional review board of
University of California at Los Angeles (Certified Exempt 02-248).
Study Design and Population
A detailed description of the study design has been published
previously [11,12]. Briefly, this was a population-based case-
control study conducted in Taixing City, Jiangsu Province, China.
Eligible cases were newly diagnosed patients with pathologically or
clinically confirmed esophageal cancer (between June 1 and
December 30, 2000), stomach cancer (between June 1 and
December 30, 2000), and liver cancer (between January 1 and
June 30, 2000) reported to the Taixing CDC Tumor Registry.
Other inclusion criteria including being 20 years of age or older, in
stable medical condition as determined by a physician, residency
in Taixing for 10 years or more, and willingness to participate. A
total of 218 esophageal cancer cases, 206 stomach cancer cases,
and 204 liver cancer cases participated, representing 67, 65 and
57%, respectively, of all newly diagnosed cancer patients.
Controls were randomly selected among healthy residents of
Taixing City with a 2:3 frequency matching ratio to the combined
case group on 5-year age categories (20–24 to 80–84), sex, and
residency (village in rural township or in an urban residential block
in central Taixing City). There are 23 townships (rural areas) and
one central town (urban area) in Taixing City. Each rural
township consists of 10–12 villages, and the central urban area
consists of 10–12 residential blocks. Other inclusion criteria were
the same as the cases. A total of 464 potential controls were
approached, and 415 (89.4%) consented to participate.
Epidemiologic data collection
All of the recruited cases and controls completed a standard
questionnaire administered by trained interviewers. Interviews
took place either at the participants’ homes, in the hospitals (for
cases), or in the county doctor’s office (for controls). Cancer cases
were usually interviewed within 6 months of diagnoses. The
questionnaire collected detailed information on demographic
factors, current height and weight, dietary history, tobacco
smoking history, alcohol drinking history, tea drinking habits,
occupational history, family history of cancers, and physical
activities.
Laboratory assays
Each study participant provided a 5-ml peripheral blood sample
after their interviews. DNA was isolated from blood clots, using the
phenol-chloroform method. Hepatitis B virus surface antigen
(HBsAg), IgG antibodies for hepatitis C virus (HCV), and IgG
antibodies for CagA-Helicobacter pylori (H. pylori) were measured
by enzyme-linked immunosorbant assay (ELISA) using kits from
the Reagent Company of the Shanghai Hospital for Infectious
Diseases (Shanghai, China), the Shanghai Huamei Biological
Company (Shanghai, China), and the Reagent Company of the
Shanghai Biotechnology Industry Park (Pudong, Shanghai,
China), respectively. Plasma aflatoxin B1 (AFB1)-albumin adduct
levels were determined by ELISA assay, as previously described
[13], using free aflatoxin (Supelco) for the aflatoxin standards. A
comparison between free and bound aflatoxin standards revealed
a log-linear relationship, allowing us to estimate the absolute
values of the samples. Plasma folate and vitamin B12 levels were
measured using a competitive radioassay with iodine 125-labeled
folate and cobalt 57-labeled vitamin B12 as tracers (Quantaphase
II B12/folate radiobinding kit, Bio-Rad, CA). Plasma total
homocysteine (tHcy) levels were measured using a commercially
available chemiluminescent immunoassay system (IMMULITE
1000 Automated Analyzer, DPC, Los Angeles, CA).
We selected eight SNPs from MTHFR, MTR, MTRR,
DNMT1, and ALDH2 genes, based on the following criteria: 1)
SNPs which are functional or potentially functional (SNPs located
in the coding, 39-, and 59-untranslated regions); 2) SNPs previously
reported to be associated with upper GI cancers; and 3) SNPs with
minor allele frequency of at least 5% in the National Center for
Biotechnology Information SNP database. Genotyping was
performed using the TaqMan (MTR rs1805087, MTRR
rs1532268/rs1801394, and ALDH2 rs886205) or the SNPlex
(DNMT1 rs2228612 and ALDH2 rs2238151) assay, as previously
described (Applied Biosystems by Life Technologies, Foster City,
CA) [14], or the PCR-RFLP analysis (MTHFR rs1801133 and
ALDH2 rs671) modified from previously published methods
[15,16]. Genotyping call rates were over 97% for TaqMan and
PCR-RFLP methods, and over 80% for the SNPlex assay.
Reproducibility was 98% for the SNPlex assay (3% random
duplicate samples) [17], and 100% for the TaqMan assay (10%
random duplicate samples).
Statistical analysis
We used Pearson’s chi-square test for Hardy-Weinberg equi-
librium (HWE) for the distributions of genotype frequencies of the
eight SNPs in the controls only. Testing for HWE among the
controls is a commonly used preliminary quality-control method in
genetic association studies to identify systematic genotyping errors
in unrelated individuals. We analyzed each SNP-cancer associa-
tion under co-dominant, log-linear, dominant, and recessive
genetic models, using unconditional logistic regression models to
calculate odds ratios (ORs) and 95% confidence intervals (CIs).
Models included age-matched categories, sex, residency (urban/
rural), education (illiteracy/primary school/higher than middle
school), body mass index (BMI, continuous), smoking pack-years
(continuous), alcohol consumption frequency (never/occasionally/
often/everyday), H. pylori infection (stomach cancer; negative/
SNPs in One-Carbon Metabolism and Upper GI Cancers
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positive), HBsAg status (liver cancer; negative/positive) and
plasma AFB1-albumin adduct levels in quintiles (liver cancer;
estimated quintile: ,222.7, 222.7–344.2, 344.2–442.6, 442.6–
588.5, and .588.5 fmol/mg). To adjust for residual confounding
effects from age, we also included the deviation of each person’s
age from the mean age in each age category [18]. We caution that
a number of adjustment variables may be affected by genetic
variations, as these variables occur afterward. At best, our
estimates are for direct genotype effects, and otherwise may be
over-adjusted or confounded by uncontrolled factors that affect
both the adjustment variables and the outcomes [19]. Thus, we
checked estimates for direct genotype effects against estimates
adjusted only for age and sex.
We further conducted stratified analyses to check heterogeneity
across strata of micronutrients or modifiable risk factors, including
plasma micronutrients (folate, vitamin B12, and tHcy), smoking
status, alcohol consumption, H. pylori infection (stomach cancer),
HBsAg status (liver cancer), and plasma AFB1 levels (liver cancer).
We used estimated median levels in controls to dichotomize
plasma levels of folate (12.76 nmol/l), vitamin B12 (228.88 pmol/
l), tHcy (9.5 mmol/l), and AFB1 (388.95 fmol/mg). We used the
dominant genetic model, which assumed that the effect of the
variant allele is dominant if the ratio of the ORs comparing
variant allele homozygotes to heterozygotes was smaller than that
comparing heterozygotes to common allele homozygotes; other-
wise we used the recessive genetic model. We assessed heteroge-
neity across strata using likelihood ratio tests by comparing models
with and without product terms.
To reduce the risks of multiple-comparison artefacts and sparse-
data bias, we used a semi-Bayes (SB) shrinkage (penalized-
likelihood) method to estimate genotype coefficients [20]; the
odds-ratio estimates we report are the antilogs of these coefficients.
Shrinkage estimation has been recommended extensively as an
alternative superior to Bonferroni in the statistical literature for
eliminating multiple-testing artefacts in comparative studies [21–
24]. In shrinkage estimation, instead of changing the alpha level,
we regress (‘shrink’) the estimates toward zero to a degree
proportional to their estimated variances and inversely propor-
tional to the prior variances v. The prior variance plays a role
analogous to the adjusted a-level, in that smaller values correspond
to more stringent rejection/detection criteria, with a=0 and v= 0
being the lower limits of adjustment at which rejection of the null
becomes impossible. At the other extreme, no adjustment occurs
when using the original value of a or a huge (effectively infinite)
value for v.
In our study, we assigned a prior variance of 0.50, and a prior
median OR=1 (no association) which results in a 95% prior
probability of falling within the interval 0.25, 4. This pulls the
observed associations toward the null to the degree that would
result if there had been a previous null experiment observing 4/
v= 8 cases total and it had been merged with the current data
[20,25]. When differing stratum-specific SNP effects were allowed,
such as in stratified analyses, the prior variance was reduced to
0.25, which corresponds to a variance of 0.50 for the coefficient of
the stratum-SNP product (interaction). For each SB posterior
estimate, we further provide the directional (one-sided) SB P-
values, which equal the posterior probability that the point
estimate is on the wrong side of the null under the fitted model and
the shrinkage priors [26,27].
To summarize the associations of the 8 SNPs for each of the
three upper GI cancers, we constructed a polygenetic risk score
(PRS) [28]. The PRS was calculated as the weighted sum of the
risk genotype (under either dominant or recessive model as in the
stratified analyses) counts, where the weight for each SNP was
determined by the semi-Bayes log OR of its association with each
cancer in the fully adjusted model. PRS was only estimated among
those with complete genotype data on all of the 8 SNPs, which
include 126 esophageal cancer cases, 125 stomach cancer cases,
142 liver cancer cases, and 287 controls. The range (maximum
minus minimum) of PRS for each cancer was divided into three
equally spaced categories; these ranges were 0.11 to 2.05 for
esophageal cancer, 0 to 1.91 for stomach cancer, and 0 to 1.40 for
liver cancer. Data analyses were performed using SAS 9.1.3 (SAS
Institute, Cary, NC).
Results
Compared to population controls, cancer cases tended to be
smokers, had lower BMI, and lower education levels (Table 1).
Esophageal and stomach cancer cases were older than the
controls, while liver cancer cases were the youngest. Liver cancer
patients had the highest male-to-female ratio of 3.53, and were
most likely to consume alcohol; esophageal cancer patients drank
more frequently than the other cancer cases and controls in this
study. For risk factors specific to each cancer site, we did not
observe differing frequency of H. pylori infection between stomach
cancer patients and controls. Compared with controls, liver cancer
patients showed a higher percentage of HBsAg positive (65 vs.
25%), anti-HCV positive (9 vs. 3%), and had higher plasma AFB1-
albumin adduct levels (30 vs. 20% in the 5th quintile).
Table 2 presents the SB odds-ratio estimates (SBOR) for each
SNP-cancer association of the eight SNPs; Table S1, S2, S3, S4,
S5, S6 shows stratified associations and Figure 1 summarizes
selected results. Genotype distributions among controls appeared
compatible with Hardy-Weinberg equilibrium, except possibly for
DNMT1 rs2228612, which had P=0.010, below the traditional
alpha level of 0.05, but larger than the Bonferroni-adjusted alpha
level of 0.05/8= 0.006 (testing all eight SNPs). However, we note
that matching may bias controls away from equilibrium if the
matching factors are associated with both the SNPs and cancer.
We have previously reported positive associations of the T allele
of MTHFR rs1801133 with stomach and liver cancer [11,12]. In
the present analysis, these associations remained apparent after
confounder adjustment and SB shrinkage (any T versus C/C, fully
adjusted SBOR: 1.79, 95% posterior limits: 1.18, 2.71 for stomach
cancer; SBOR: 1.51, 95% posterior limits: 0.98, 2.32 for liver
cancer). In stratified SB analyses, the association between
MTHFR rs1801133 and stomach cancer appeared stronger
among individuals who had lower plasma folate levels, higher
plasma vitamin B12 or tHcy levels, and among smokers (Figure 1).
There was no clear association of MTHFR rs1801133 with
esophageal cancer (Table 2 and Tables S1, S2, S3, S4, S5).
While there was no clear overall association between SNPs in
MTR and MTRR and any cancer in main effect analyses
(Table 2), heterogeneity of association was suggested in stratified
analyses on alcohol consumption, including associations of MTR
rs1805087 with liver cancer (homogeneity P=0.021), and MTRR
rs1801394 with both esophageal (homogeneity P=0.005) and
stomach cancer (homogeneity P=0.004). While G allele carriers
of MTR rs1805087 were inversely associated with liver cancer
among non-drinkers (SBOR: 0.57, 95% posterior limits: 0.31,
1.04), they were positively associated with liver cancer among
drinkers (SBOR: 1.48, 95% posterior limits: 0.85, 2.57) (Figure 1).
Similarly, G allele carriers of MTRR rs1801394 were inversely
associated with esophageal and stomach cancer among non-
drinkers (SBOR: 0.59, 95% posterior limits: 0.37, 0.94 for
esophageal cancer; SBOR: 0.49, 95% posterior limits: 0.30, 0.79
for stomach cancer) but positively associated with cancer among
SNPs in One-Carbon Metabolism and Upper GI Cancers
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drinkers (SBOR: 1.56, 95% posterior limits: 0.95, 2.56 for
esophageal cancer; SBOR: 1.39, 95% posterior limits: 0.83, 2.32
for stomach cancer) (Figure 1).
For DNMT1 polymorphism, rs2228612 was inversely associat-
ed with esophageal cancer in the dominant genetic model (any G
versus A/A, SBOR: 0.60, 95% posterior limits: 0.39, 0.94)
(Table 2). Among three ALDH2 SNPs, rs671 was associated with
esophageal cancer in the recessive genetic model (A/A versus any
G, SBOR: 1.76, 95% posterior limits: 0.96, 3.24). In stratified
adjusted analyses, ALDH2 rs671 appeared associated with
esophageal cancer among individuals with lower plasma folate
levels (A/A versus any G, SBOR: 2.12, 95% posterior limits: 1.01,
4.44) (Figure 1). The ALDH2 rs2238151 appeared inversely
associated with liver cancer when comparing T allele carriers to
those with the C/C genotype (age and sex-adjusted SBOR: 0.47,
95% posterior limits: 0.24, 0.92). While we did not find
associations between ALDH2 rs886205 and cancer susceptibility
in main effect analyses, stratum-specific SBOR suggested that
ALDH2 rs886205 was positively associated with stomach cancer
among participants with higher plasma vitamin B12 levels (SBOR:
1.87, 95% posterior limits: 1.09, 3.20) (Figure 1).
Except for analysis on single SNP models, we also did joint
SNPs analysis by including all of the 8 SNPs in a model (Table 3).
The results from joint SNPs analysis suggested similar associations
as in the single SNP models, but the 95% posterior intervals were
wider.
The analysis on PRS suggested roughly a doubling of odds for
esophageal and liver cancers among individuals in the highest PRS
category compared to those in the lowest category (SBOR: 2.06;
95% posterior limits: 1.13, 3.77 for esophageal cancer and SBOR:
2.09, 95% posterior limits: 1.05, 4.17 for liver cancer), with
somewhat less consistency across categories for stomach cancer. In
the continuous PRS analysis, the results suggested a doubling of
odds for these three upper GI cancers with one unit (in log OR)
increase of PRS (Table 4). We caution however that PRS analyses
do not account for the score construction from the data, and thus
may overestimate effects and underestimate variability in the
resulting estimates.
Discussion
We examined the associations between eight SNPs in genes
involved in the one-carbon metabolic pathway and susceptibility of
esophageal, stomach, and liver cancers in a Chinese population.
After applying SB shrinkage methods and controlling for potential
confounders, we observed that any T genotype of MTHFR
rs1801133 was positively associated with both stomach and liver
cancer. We also found an inverse association between the variant
G allele of DNMT1 rs2228612 and esophageal cancer. In
addition, our study suggested potential OR variations across strata
of alcohol consumption, including associations of MTRR
rs1801394 with esophageal and stomach cancer, and MTR
rs1805087 with liver cancer. The odds for upper GI cancers were
roughly doubled for Chinese participants with one unit (in log OR)
increase of PRS.
In one-carbon metabolism, MTHFR irreversibly catalyzes the
conversion of 5,10-methylenetetrahydrofolate (5,10-methyle-
neTHF) to 5-methyltetrahydrofolate (5-methylTHF). The 5,10-
methyleneTHF is essential in purine and thymidilate synthesis,
and 5-methylTHF is a co-substrate for remethylation of homo-
cysteine to methionine, which is further converted to SAM for
methylation reactions [5]. The MTHFR C677T (rs1801133)
polymorphism, which results in an alanine to valine substitution,
leads to reduced MTHFR enzyme activity [29], decreased 5-
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methylTHF and an accumulation of 5,10-methyleneTHF in red
blood cells [30].
Low MTHFR activity is associated with increase cancer risk due
to low blood 5-methylTHF and impaired DNA methylation.
Conversely, it could reduce cancer risk by increasing the
availability of 5,10-methyleneTHF for normal DNA synthesis
and preventing uracil misincorporation and chromosomal break-
age [5]. Although evidence in support of these hypotheses is weak
and inconsistent [5], an in vitro study suggested that the effect of
MTHFR rs1801133 on DNA stability and methylation is site-
specific and may depend on folate availability [31]. When folate
supply is adequate or high, the T allele of MTHFR is associated
with increased genomic DNA methylation in colon cancer cells,
but decreased DNA methylation in breast cancer cells. When
folate supply is limited, this variant is associated with decreased
and unchanged DNA methylation in colon and breast cancer cells,
respectively [31]. Uracil misincorporation is decreased in colon
cancer cells expressing the MTHFR T allele, and increased in
breast cancer cells expressing the same variant [31]. This site-
specific difference may partly explain the difference in cancer risk
associated with the MTHFR rs1801133 polymorphism [4]. In
epidemiologic studies, the T allele appears to decrease the risk of
colorectal and breast cancers [32,33], but increase the risk of
cancers of the esophagus, stomach, liver, bladder, cervix uteri, and
lung [2–4,34–36].
In the present analysis using SB shrinkage, we confirmed our
previous findings of positive associations between the T allele of
MTHFR rs1801133 and cancers of the stomach and liver in this
Taixing population [11,12], implying that the disturbance of DNA
methylation resulting from this variant plays a major role in
stomach and liver carcinogenesis. Recent meta-analyses reported
similar associations (T/T versus C/C, OR: 1.40, 95% CI: 1.19–
1.66 for stomach cancer; OR: 1.21, 95% CI: 0.95–1.56 for liver
cancer) [3,4]. In addition, Zacho et al. [4] reported a larger
Figure 1. Selected semi-Bayes stratum-specific associations. Selected semi-Bayes stratum-specific associations between SNPs in MTHFR, MTR,
MTRR, DNMT1, ALDH2, and upper GI cancer susceptibility, by plasma levels of micronutrients (folate, vitamin B12, and homocysteine) and
environmental factors (smoking, alcohol drinking, H. pylori CagA status, HBsAg status, and plasma AFB1-albumin adduct levels). Semi-Bayes adjusted
ORs (SBOR) and 95% posterior limits were under dominant genetic models, except for the SBOR relating ALDH2 rs671to esophageal cancer, where
recessive genetic model was used. P* denotes P-value for homogeneity test.
doi:10.1371/journal.pone.0109235.g001
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association between MTHFR rs1801133 and stomach cancer
among study populations without folic acid fortification (OR: 1.60,
95% CI: 1.36–1.88), as compared to those with fortification (OR:
1.15, 95% CI: 0.81–1.63), which is similar to our finding of a
stronger association among individuals with lower plasma folate
levels. For esophageal cancer, our data suggested an increased risk
among MTHFR rs1801133 T allele carriers (any T vs. C/C,
SBOR: 1.25, 95% posterior limits: 0.85, 1.84), which is consistent
with findings from a meta-analysis of 19 studies (C/T versus C/C,
OR: 1.47, 95% CI: 1.32–1.63; T/T versus C/C, OR: 1.69, 95%
CI: 1.49–1.91) [2].
MTR and MTRR are two other important enzymes involved in
one-carbon metabolism. MTR catalyzes the methylation of
homocysteine to methionine. MTR A2756G (rs1805087), a
common SNP leading to the substitution of aspartic acid with
glycine, has been largely studied. However, no apparent associ-
ations have been observed with cancer at the following sites: lung,
prostate, head and neck, bladder, esophagus, stomach, breast, or
colon and rectal [37–46]. MTRR regenerates a functional MTR
via reductive methylation. Two common polymorphisms, MTRR
A66G (rs1801394, converts isoleucine to methionine) and C524T
(rs1532268, changes serine to leucine), have been indicated to
regenerate MTR less efficiently [47]. G allele carriers of MTRR
rs1801394 have been associated with increased risk for hepato-
cellular carcinoma (HCC) [48]. Conversely, associations are
inconsistent with other malignancies, including esophageal squa-
mous cell carcinoma (ESCC), stomach cancer, and colorectal
cancer [37,44,49–53]. Most studies that have investigated MTRR
rs1532268 reported no associations with colorectal, gastric, breast,
and lung cancer [44,51,53–56]. One should bear in mind however
that apparent inconsistencies and reports of no association may
only reflect expected variation in P-values (‘‘statistical signifi-
cance’’) rather than any real conflicts.
Our study observed odds-ratio variation of the associations
between these MTR/MTRR polymorphisms and upper GI
cancers across alcohol consumption, even after conservative SB
shrinkage. Alcohol consumption appeared to have modified odds-
ratios relating MTR rs1805087 to liver cancer, and MTRR
rs1801394 to esophageal and stomach cancer. G allele carriers of
these two SNPs were positively associated with cancer among
drinkers, and inversely associated with cancer among non-
drinkers. Matsuo et al., observed a similar OR variation [57]:
G/G genotype carriers of MTR rs1805087 showed higher
colorectal cancer risk among alcohol drinkers and lower risk
among non-drinkers. Although the functional effect of MTR/
MTRR polymorphisms has not been established, our results are
biologically plausible as alcohol can disrupt one-carbon metabo-
lism by inhibiting folate absorption, suppressing SAM synthesis,
and impairing DNA methylation [6]. Alcohol can also cause
inhibition of methionine synthase activity [6]. Therefore, it is
possible that the variant allele of these two MTR/MTRR
polymorphisms is protective for the upper GI cancers under the
environment without alcohol exposures. However, it becomes
deleterious when one-carbon metabolism is disrupted by alcohol
and its metabolites.
ALDH2 is involved in alcohol metabolism by oxidizing
acetaldehyde, a group 2B human carcinogen, to acetic acid. The
ALDH2 rs671 polymorphism—a well-known variant that occurs
exclusively in Asian populations—causes a lower catalytic
efficiency of ALDH2, and hence renders lower ability to eliminate
acetaldehyde [58]. The ALDH2 rs671 A allele (slow type) has been
associated with increased risk of head and neck cancer, as well as
esophageal cancer [59,60]. Consistent with previous findings, we
observed a positive association between the A/A genotype and
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esophageal cancer in this study, and further reported a stronger
association among individuals with lower plasma folate levels.
Acetaldehyde also interferes with folate metabolism [6]. It is
possible that the deleterious effect associated with rs671 polymor-
phism is more prominent under the condition of lower folate
supply. Another common variation in the ALDH2 gene—
rs886205 with a G to A substitution in the promoter region—
has been suggested to be functional. Chou et al., reported that the
promoter constructs encoded by the G allele were more active
than the A allele in hepatoma cells [61]. The G allele of rs886205
was reported to be associated with increased risk of ESCC [62,63]
but not with stomach [64,65] and colorectal cancer [66]. It also
showed inconsistent results with head and neck cancer [67–69].
We observed a positive association between the A allele of
rs886205 and stomach cancer among those with higher plasma
vitamin B12 levels. Although ALDH2 rs886205 is suggested to be
a functional polymorphism in hepatoma cells [61], further
functionality studies are warranted.
There are several limitations due to the case-control design and
the multiple comparisons in this study. Because we were not able
to recruit all of the identified cases and controls, selection bias may
occur if participation is affected by an un-identified factor which is
associated with both the SNPs and cancer. On the other hand,
cancers of the esophagus, stomach, and liver are fatal, and some
patients with late clinical stages at diagnosis were either too ill to
participate or passed away. This selection of patients may have
resulted in biased estimates if the SNPs under study are associated
with disease progression. Also, we collected plasma samples after
cancer diagnoses. By stratification on plasma micronutrients, we
may have introduced a ‘‘collider-stratification bias’’ if disease
states, as well as treatments and/or diet and behavior changes
among cancer patients would affect the levels of these biomarkers
[70]. However, given that there may be only a weak association
between SNPs and plasma micronutrients in one-carbon meta-
bolic pathway [71], we believe that the size of the bias would be
small. In addition, we conducted many comparisons and subgroup
analyses, which led us to employ semi-Bayes shrinkage estimation
to reduce the risk of misleading results. Using these methods, in
this Chinese population, several polymorphisms in the one-carbon
metabolic pathway appear to be associated with esophageal,
stomach, and liver cancer, with heterogeneity across strata of
alcohol consumption for the odds ratios relating MTR/MTRR
polymorphisms to these cancers, suggesting potential interactions
between alcohol drinking and genes of the one-carbon metabolic
pathway. Confirmation of these results and research on the
underlying mechanisms are needed.
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